Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - January 2017
Webcast ImageWebcast - Live
Q4 2016 Juno Therapeutics Earnings Conference Call
March 01, 2017 at 2:00 p.m. PT
Q4 2016 Juno Therapeutics Earnings Conference Call
Wednesday, March 1, 2017 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Juno Therapeutics at Leerink Partners 6th Annual Global Healthcare Conference
February 15, 2017 at 10:00 a.m. ET
Juno Therapeutics at Leerink Partners 6th Annual Global Healthcare Conference
Wednesday, February 15, 2017 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development OperationsPrinter Friendly Version
Jan. 03, 2017Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
Dec. 20, 2016Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell LymphomaPrinter Friendly Version

Upcoming Events

DateTitle
Mar. 01, 2017
2:00 p.m. PT
Q4 2016 Juno Therapeutics Earnings Conference Call

Past Events

DateTitle
02/15/17 10:00 a.m. ET
Juno Therapeutics at Leerink Partners 6th Annual Global Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$22.12
Change0.00 (0.00%)
Volume0
Data as of Feb. 23, 2017 4:00 p.m. ET